Fig. 3: Best percent change in lesion size from baseline in the second-line subgroup. | npj Breast Cancer

Fig. 3: Best percent change in lesion size from baseline in the second-line subgroup.

From: Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Fig. 3

Waterfall plot showing best percent change from baseline in the sum of the diameters of target lesions in second-line patients treated with SG (a) or TPC (b). Assessed by independent central review in the brain metastasis-negative population. Second-line patients were defined as those who received 1 line of therapy in the metastatic setting and recurred ≤12 months after (neo)adjuvant chemotherapy, prior to study enrollment. SG sacituzumab govitecan, TPC treatment of physician’s choice.

Back to article page